Firms

Illumina Ventures

Illumina Ventures

Foster City, California, United States · United States · Europe

illuminaventures.comreports.adviserinfo.sec.gov

Illumina Ventures is an independently managed venture investor focused on genomics, precision health, life-science tools, diagnostics, therapeutic platforms and related digital-health and planetary-health applications. Nicholas (Nick) Naclerio founded the firm in 2016. Its legal manager is IIF Management Company, LLC (CRD 283782; SEC exempt reporting adviser file 802-107904), headquartered in Foster City, California. It operates separately from Illumina Inc., the sequencing company and strategic anchor investor in its funds. The current public team includes investment professionals, scientists, US and UK laboratory staff, venture partners, external advisers and operations staff. Chief AI Scientist Martin Moorhead contributes expertise in machine learning, computational biology and genomics. The published portfolio includes AI drug-discovery companies Iambic Therapeutics and DeepSeq.AI, AI and automation platform Bullseye Biosciences, and machine-learning company Integrated Biosciences. Encoded Therapeutics and Kallyope establish genetic-medicine and neuroscience relevance. These investment themes do not establish regulatory approval or clinical efficacy for investigational portfolio products. The firm manages the legally separate Illumina Innovation Funds I, II and III. Fund I announced a $230 million close on October 16, 2017; Fund II announced a $325 million close on September 20, 2021. Fund III reported $60 million sold in its August 29, 2025 Form D amendment; that disclosed partial raise is distinct from its $200 million offering target and an unverified final close. Current fund asset values and earlier aggregate capital-under-management figures are not additional cash raised. Alamar Biosciences investments are attributed to the actual participating fund vehicles under this manager, preserving their distinctions from corporate Illumina and personal investments.

Founded
2016
Type
Venture capital

Funds3

  • Illumina Innovation Fund II, L.P.$325M

    ExactLP/GP verified2026FormADV. OwnmanagerSeptember20,2021 closingrelease confirms325MUSDcommittedsecondfund. IlluminaInc anchor andmajorityotherLPs; reported560Mtotalcapitalundermanagement isseparatemetric, notnewcash.

  • Illumina Innovation Fund I, L.P.$230M

    ExactLP andGP identified2026FormADV. Ownissuer PRNewswire release republishedOctober16,2017 confirms230MUSDactualfirstfundclose,includinginitial100M2016IlluminaLPanchor; nottwoadditionalfunds. The originalwireURL now404, accessibleissuerreprintqualified.

  • Illumina Innovation Fund III, L.P.$60M

    ExactDelawareLP organized2023,GPseparate, current2026ADV confirmsvehicle. SECFormD/A signedAugust29,2025 reports60MUSDsoldof200Moffering; original2024zero-sold300Moffering waschanged, notactualclose. FirstsaleAugust27,2024 isnotfinalfundclosingday; announcedAtNULL. Amountrecordsdisclosedpartialfundinterest saleasof2025filing, notfinalfundsize/currentAUM/target. Actual2026Alamarparticipation confirmsoperatingfundbutdoesnotestablishcurrentfinalclose.

Team

Operations and support

Abhijit Ron MazumderAbhijit Ron MazumderPartner
Bill RastetterBill RastetterAdvisor
Charles WhiteCharles WhitePrincipal
David C. DuffyDavid C. DuffyEntrepreneur in Residence
David WaltDavid WaltAdvisor
Donal DelaneyDonal DelaneyChief Financial Officer
Ivan CoulterIvan CoulterVenture Advisor
Jerry SteinerJerry SteinerAdvisor
Jessica WongJessica WongController
Malek FahamMalek FahamChief Scientist
Mara AspinallMara AspinallPartner
Martin MoorheadMartin MoorheadChief AI Scientist
Natalie NakamotoNatalie NakamotoExecutive Assistant, Office Manager
Nicholas NaclerioNicholas NaclerioFounding Partner
Ronan ByrneRonan ByrneVenture Advisor
Rose LaiRose LaiSenior Executive Assistant
Shalaka WahaneShalaka WahaneLead Scientist, Head of Lab Operations (US site)
Timothy StenzelTimothy StenzelAdvisor
Tom WillisTom WillisVenture Partner
William ByrneWilliam ByrneSenior Associate
Wouter MeulemanWouter MeulemanPartner
Yogesh KamraYogesh KamraHead of Lab Operations (UK site)
Yuling LuoYuling LuoVenture Partner

Co-investing

ARCH Venture Partners
+ND Capital
M Ventures
Qiming Venture Partners
Alexandria Venture Investments

Investments

$215M2021-11-09Arbor BiotechnologiesARCH Venture Partners, TCV, Temasek Holdings (Private) Limited, Tao Capital Partners, Redpoint Ventures, S32, Illumina Ventures, Section 32, Piper Heartland Healthcare Capital
$—Unknown dateIntegrated BiosciencesIllumina Ventures
$219M2026-04-20Alamar BiosciencesIllumina Ventures
$56M2026-01-11Alamar BiosciencesIllumina Ventures, Sands Capital, Braidwell LP, T. Rowe Price Investment Management Inc.
$27M2026Lightcast BioARCH Venture Partners, +ND Capital, M Ventures, Illumina Ventures
$—2025-12-11MyOme, Inc.Sequoia, Duquesne Family Office, Illumina Ventures
$55M2025-06-17Corvia MedicalGeneral Catalyst, Illumina Ventures, Third Rock Ventures, Accelmed Partners, Hemant Taneja
$175M2024-10-23Alpha-9 OncologyLightspeed, General Catalyst, Illumina Ventures, BVF Partners L.P., Longitude Capital, Agent Capital, Delos Capital
$128M2024-02-26Alamar BiosciencesSands Capital, Illumina Ventures, Sherpa Healthcare Partners, Qiming Venture Partners
$49M2023-08-18Lightcast DiscoveryARCH Venture Partners, +ND Capital, OKX Ventures, M Ventures, Illumina Ventures